High Dose Intravenous Busulfan and Melphalan Followed By Bortezomib (BuMelVel) As Conditioning With Autologous Stem Cell Transplantation (ASCT) For Patients With Multiple Myeloma (MM)

被引：0
|
作者：
Sterrenberg, Danielle
Stiff, Patrick J.
Parthasarathy, Mala
Go, Aileen
Smith, Scott E.
Rodriguez, Tulio E.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.3376.3376
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3376
引用
收藏
页数：2
相关论文
共 50 条
  • [1] High Dose Intravenous Busulfan (BU) and Melphalan (MEL) Followed by Bortezomib (BTZ) as Conditioning with Autologous Peripheral Blood Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (MM)
    Rodriguez, Tulio E.
    Stiff, Patrick J.
    Smith, Scott E.
    Kaufman, Jonathan L.
    Lee, Mary
    Parthasarathy, Mala
    Earley, Zachary M.
    Lonial, Sagar
    Vesole, David H.
    BLOOD, 2010, 116 (21) : 582 - 582
  • [2] Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
    Rodriguez, Tulio E.
    Hari, Parameswaran
    Stiff, Patrick J.
    Smith, Scott E.
    Sterrenberg, Danielle
    Vesole, David H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (08) : 1391 - 1396
  • [3] Busulfan and melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
    Jung, Sung-Hoon
    Lee, Je-Jung
    Kim, Jin Seok
    Min, Chang-Ki
    Kim, Kihyun
    Choi, Yunsuk
    Eom, Hyeon-Seok
    Joo, Young Don
    Kim, Sung-Hyun
    Kwak, Jae-Yong
    Kang, Hye Jin
    Lee, Jae Hoon
    Lee, Ho Sup
    Mun, Yeung-Chul
    Moon, Joon Ho
    Sohn, Sang Kyun
    Park, Seong Kyu
    Park, Yong
    Shin, Ho-Jin
    Yoon, Sung-Soo
    BONE MARROW TRANSPLANTATION, 2018, 53 : 262 - 263
  • [4] Autologous stem cell transplantation (ASCT) after conditioning therapy with intermediate dose melphalan, bortezomib,thalidomide, dexamethasone (MVTD) in relapsed multiple myeloma (MM) patients
    Scalzulli, P. R.
    Bodenizza, C.
    Carella, A. M.
    Dell'Olio, M.
    Falcone, A. P.
    Greco, M. M.
    La Sala, A.
    Mantuano, S.
    Melillo, L.
    Merla, E.
    Nobile, M.
    Sanpaolo, G.
    Valvano, M. R.
    Cascavilla, N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 212 - 212
  • [5] Single daily dose of intravenous busulfan and melphalan as conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation
    de la Rubia, J.
    Lahuerta, J.
    Gonzalez, J.
    Solano, C.
    Rivas, P.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S323 - S323
  • [6] TIMING OF HIGH DOSE MELPHALAN (HDM) AND OUTCOMES FOR AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS WITH MULTIPLE MYELOMA (MM)
    Mahindra, A.
    Bolwell, B.
    Rybicki, L.
    Sobecks, R.
    Pohlman, B.
    Andresen, S.
    Earl, M.
    Dean, R.
    Copelan, E.
    Kalaycio, M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 41 - 42
  • [7] Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma
    Buadi, Francis K.
    Gertz, Morie A.
    Laplant, Betsy R.
    Halvorson, Alese
    Lacy, Martha Q.
    Hayman, Suzanne R.
    Dingli, David
    Kapoor, Prashant
    Gonsalves, Wilson I.
    Miceli, Teresa
    Brandes, Eva
    Stafford, Scott L.
    Martenson, James A.
    Hogan, William J.
    Kumar, Shaji K.
    BLOOD, 2016, 128 (22)
  • [8] Busulfan / Melphalan / Bortezomib (Bu-Mel-Vet) Vs. High Dose Melphalan As Conditioning Regimen For Autologous Hematopoietic Cell Transplantation In Multiple Myeloma (MM)
    Rodriguez, Tulio E.
    Hari, Parameswaran
    Stiff, Patrick J.
    Zhong, Xiaobo
    Sterrenberg, Danielle
    Vesole, David H.
    BLOOD, 2013, 122 (21)
  • [9] Melphalan Dose Intensity for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma
    Srour, Samer A.
    Milton, Denai
    Bashir, Qaiser
    Mehta, Rohtesh S.
    Delgado, Ruby
    Rondon, Gabriela
    Nieto, Yago
    Hosing, Chitra M.
    Popat, Uday R.
    Ciurea, Stefan O.
    Patel, Krina
    Lee, Hans C.
    Manasanch, Elisabet
    Thomas, Sheeba
    Weber, Donna
    Orlowski, Robert Z.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [10] Autologus stem cell transplantation (ASCT) conditioning therapy intermediate dose Melphalan, Bortezomib, Thalidomide, Dexamethasone (MVRO) in relapsed multiple myeloma (MM)
    Scalzulli, P. R.
    Bodenizza, C. A.
    Carella, A. M.
    Dell'Olio, M.
    Falcone, A. P.
    Greco, M. M.
    La Sala, A.
    Mantuano, S.
    Melillo, L.
    Merla, E.
    Nobile, M.
    Sanpaolo, G.
    Musto, P.
    Valvano, M. R.
    Cascavilla, N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 437 - 437
12345